[10], and other investigators also demonstrated that PPARγ plays a critical role in resisting oxidant-induced lung injury [11, 12], reducing inflammation [13] and alleviating pulmonary fibrosis [14] in both mice and humans, suggesting that PPARγ may be a potential therapeutic target for ARDS. This evidence concerns the gene PPARG and pulmonary fibrosis.